Mesenchymal stem cell therapy - StemMedical
Alternative Names: STEM-OA - StemMedicalLatest Information Update: 26 Apr 2023
At a glance
- Originator StemMedical
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 03 Apr 2023 StemMedical has patent protection for mesenchymal stem cell therapy worldwide (StemMedical pipeline, April 2023)
- 03 Apr 2023 Preclinical trials in Osteoarthritis in Denmark (Intra-articular) before April 2023 (StemMedical pipeline, April 2023)
- 03 Apr 2023 StemMedical plans a phase I trial in Osteoarthritis in Denmark (Intra-articular, Injection) in November 2023 (NCT05789719)